Vera Therapeutics Inc

Vera Therapeutics has received accelerated approval from the U.S. Food and Drug Administration for TRUTAKNA to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. The approved dose is 150 milligrams injected subcutaneously once weekly via an autoinjector. In a prespecified interim analysis of the ongoing ORIGIN 3 trial, TRUTAKNA achieved a 46 percent reduction in proteinuria from baseline and a 42 percent reduction compared to placebo at 36 weeks. Continued approval depends on verification of clinical benefit in the same trial, with results on kidney function expected in the third quarter of 2026. TRUTAKNA enters a competitive market that includes Filspari, Tarpeyo, Fabhalta, Vanrafia, and Voyxact.

Scilex Holding jumped 7% in premarket trading after announcing a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment group iHolding Group LLP. Vera Therapeutics gained 6% ahead of its July 7 Prescription Drug User Fee Act decision for atacicept, its investigational treatment for IgA nephropathy. Solaris Energy Infrastructure rose 3.9% after Wolfe Research initiated coverage with an Outperform rating and a $120 price target, and the company also announced the acquisition of power generation services provider Global Energy Services Alliance for approximately $55 million in cash and stock. Strategy climbed 3.4% as investors continued to digest the company's newly adopted Digital Credit Capital Framework, which authorizes the selective monetization of up to $1.25 billion of its Bitcoin holdings to bolster liquidity, fund preferred dividends and support share repurchases.

Wells Fargo reiterated a Buy rating on Vera Therapeutics with a $70 price target, while LifeSci Capital maintained a Buy rating and set a $90 target, citing strong potential for its lead drug atacicept in treating IgA nephropathy. The company's June 2, 2026 agreement with the FDA allows earlier analysis of kidney function data from its Phase III ORIGIN 3 study, and positive results could enable a full approval application in the fourth quarter of 2026. Atacicept is already under priority review for accelerated approval, and broader patient eligibility could expand its market opportunity.

The IgA nephropathy clinical trial space is intensifying, with more than 25 companies actively developing over 30 pipeline drugs, according to a new report from DelveInsight. Key players include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca, Roche, Ionis Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, and others. Promising therapies in various trial phases include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS, Sefaxersen, TAK-079, ARO-C3, NM8074, WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, and IFX 301. Approximately 12 or more drugs are in late-stage development, targeting mechanisms such as Complement Factor B inhibition, BAFF and APRIL antagonism, antibody-dependent cell cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 antagonism. Recent milestones include positive Phase III data for Povetacicept and Atacicept, and publication of telitacicept results in the New England Journal of Medicine.

Three biotech companies are approaching significant catalysts that could reshape their futures. Vera Therapeutics is preparing a Biologics License Application for atacicept, an investigational drug for IgA nephropathy, with an accelerated timeline following FDA alignment on a revised analysis plan expected in the third quarter. Krystal Biotech, which already markets the first gene therapy approved for a skin condition, anticipates top-line results from its KB803 corneal abrasion trial by year-end and a registrational data readout for KB801 in 2026. ADMA Biologics, which has multiple marketed products and reported 28% year-over-year revenue growth from ASCENIV last quarter, is advancing SG-001, an investigative hyperimmune globulin candidate for pneumococcal disease, while also benefiting from margin expansion driven by new manufacturing efficiencies.

Vera Therapeutics reached an agreement with the U.S. Food and Drug Administration on an accelerated timeline for its ORIGIN 3 eGFR analysis plan to support full regulatory approval of atacicept for adults with IgA nephropathy. The company expects to release eGFR findings in the third quarter of 2026 and plans to file a supplemental Biologics License Application in the fourth quarter of 2026, contingent on the data. The modified regulatory approach was supported by past eGFR data from the ORIGIN Phase 2b clinical trial. Founder and CEO Marshall Fordyce noted the medication's potential to be the first licensed treatment targeting both BAFF and APRIL for adult IgAN patients.